LL-37 vs KPV

What Are LL-37 and KPV?

LL-37 (Human cathelicidin antimicrobial peptide LL-37) is a Antimicrobial peptide, host defense peptide. Endogenous human antimicrobial peptide; the only human member of the cathelicidin family; produced by neutrophils, macrophages, and epithelial cells. It is researched for broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement.

KPV (Lysine-Proline-Valine tripeptide) is a Alpha-MSH fragment, NF-κB inhibitor. C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH), naturally occurring from proteolytic cleavage. It is researched for anti-inflammatory, IBD reduction, intestinal barrier repair, skin inflammation reduction, immune modulation.

While both are popular research peptides, they work through fundamentally different mechanisms and serve different primary purposes.

How Do LL-37 and KPV Work Differently?

LL-37 mechanism: Kills pathogens through multiple mechanisms: converts from random coil to α-helix structure, burrows into bacterial membranes causing permeabilization (carpet model), generates oxidative stress in bacterial cells, and disrupts biofilms and viral envelopes. Also immunomodulatory — activates chemokine receptors and enhances inflammatory response. Effective against 38+ bacteria, 16 fungi, and 16 viruses.

KPV mechanism: Inhibits nuclear factor-kappa B (NF-κB) activation through PepT1 transporter-mediated cellular uptake, completely independent of melanocortin receptors. Blocks NF-κB nuclear import and suppresses pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) at nanomolar concentrations. Also inhibits MAPK inflammatory signaling cascade.

These distinct mechanisms are why the two peptides are often used for different research goals — or combined to target multiple pathways.

How Do the Dosing Protocols Compare?

LL-37: 100-500 mcg (topical/local application) administered topical or local application as needed via topical wound application, local injection, intranasal. Half-life: rapidly degraded by proteases; major clinical limitation. Cycle: acute use as needed.

KPV: 200-500 mcg daily administered once or twice daily via oral (most studied), intranasal, subcutaneous. Half-life: not published. Cycle: 4-8 weeks.

Use our peptide calculator for reconstitution math for either compound.

How Do the Benefits Compare?

LL-37 benefits: broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement.

KPV benefits: anti-inflammatory, IBD reduction, intestinal barrier repair, skin inflammation reduction, immune modulation.

The overlap in benefits determines whether these peptides compete for the same use case or complement each other in a stack.

How Do the Side Effects Compare?

LL-37: Dose-dependent cytotoxicity to human cells above 75 mcg/mL. Hemolytic effects at high concentrations. Proteolytic degradation limits bioavailability. Potential immune overstimulation.

KPV: No serious adverse events in preclinical studies. Theoretical potential for immune suppression at very high doses given NF-κB inhibition. GI upset possible with oral administration.

Can You Stack LL-37 and KPV Together?

Many researchers combine LL-37 and KPV in stacking protocols. The different mechanisms mean they can potentially provide complementary effects without competing for the same receptors.

Pairs with BPC-157 for wound healing — LL-37 handles antimicrobial defense while BPC-157 promotes tissue repair. See our stacking guide for general principles.

Which Is Better: LL-37 or KPV?

There is no universal answer. LL-37 may be preferable for researchers focused on broad-spectrum antimicrobial activity, while KPV is stronger for anti-inflammatory.

For the most comprehensive results, many researchers combine both. Review each compound's individual guide for detailed protocols: LL-37 | KPV.

Frequently Asked Questions